Shareholding for the Period Ended December 31, 2017
Orchid Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly Click here19-01-2018
19-01-2018
Statement Of Investor Complaints For The Quarter Ended December 31,2017
Statement of investor complaints for the quarter ended December 31,201716-01-2018
Updates
RECEIPT OF ESTABLISHMENT INSPECTION REPORT (EIR)FROM USFDA-POST MARKETING ADVERSE DRUG EXPERIENCE REPORTING INSPECTION(PADE)08-01-2018
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Adurjee & Bros Private Limited03-01-2018
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Adurjee & Bros Pvt Ltd22-12-2017
Clarifies on News item
With reference to news flashed on economictimes.indiatimes.com dated December 18, 2017 quoting "Aurobindo, Dr Reddy's Laboratories frontrunners to buy out bankrupt Orchid Pharma". Orchid Pharma Ltd has submitted to BSE a copy of Clarification is enclosed.18-12-2017
Clarification sought from Orchid Pharma Ltd
The Exchange has sought clarification from Orchid Pharma Ltd on December 18, 2017 with reference to news flashed on economictimes.indiatimes.com dated December 18, 2017 quoting "Aurobindo, Dr Reddy's Laboratories frontrunners to buy out bankrupt Orchid Pharma".The reply is awaited.18-12-2017
Orchid Pharma gets USFDA nod for ANDA for schizophrenia drug
Shares of the company were trading 4.87 per cent up at Rs 18.30 on BSE13-12-2017